Drug intelligence / Profile preview

IDC225

Development stage: Preclinical
Lead developer: Prestige Biopharma Innovative Discovery Centre
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Ophthalmic

Overview

IDC225 is a preclinical-stage innovative monoclonal antibody being developed by Prestige Biopharma (PBK). It is part of the company's "Innovative Drug Candidate" (IDC) portfolio and is specifically designed for ocular administration to treat undisclosed ophthalmic conditions. The candidate is described as being part of an ocular platform, suggesting a focus on specialized delivery or targeting within the eye. Details regarding its specific molecular target and the primary indication are currently proprietary and have not been publicly disclosed.

Beyond the preview

Go deeper on IDC225.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC225.

Explore the full profile